FDA
-
-
-
-
-
-
-
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
-
-
-
-
-
-
-
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
-
-
-
-
-
-
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
-
-
-
-
-
-
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on WAVE Life Sciences (WVE)
-
-
-
-
-
-
-
Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
-
328,249 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

